About B Isomorphic
Isomorphic Labs is pioneering a new era of drug discovery by applying frontier artificial intelligence to unlock deeper scientific insights and accelerate the development of life-changing medicines. Founded by Sir Demis Hassabis, the company builds upon and extends beyond the Nobel Prize-winning AlphaFold system to advance human health through digital biology. The company's interdisciplinary team brings together drug discovery experts and machine learning specialists who have developed powerful predictive and generative AI models that operate at digital speed. Their foundational Drug Design Engine is capable of generating drug candidates against challenging targets across multiple modalities including small molecules, antibodies, peptides, and molecular glues. Isomorphic Labs has established strategic research collaborations with leading pharmaceutical companies including Novartis, Eli Lilly and Company, and Johnson & Johnson. These partnerships combine Iso's AI-first approach with partners' extensive drug discovery expertise to identify novel molecules and address diseases that have historically been out of reach. The company's mission reflects the belief that there is an underlying symmetry between biology and information science—an isomorphism that AI can harness to model complex biological phenomena and develop innovative medicines to treat and cure some of the world's most devastating diseases.
Mission & Story
Mission
Our mission is to solve all disease
Founding Story
Founded by Sir Demis Hassabis based on the belief that there is no more important application for AI than helping to improve human health. The company was created to build on and beyond the Nobel Prize-winning AlphaFold system developed at Google DeepMind.
Who It Serves
Milestones & Awards
Recent Milestones
Series B investment round announced February 2025; Drug Design Engine unveiled February 2025; Johnson & Johnson collaboration announced January 2026; Novartis collaboration expanded February 2025 (adding up to three additional research programs); $600M external investment round March 2025; Dr. Ben Wolf appointed Chief Medical Officer and US presence established June 2025; Max Jaderberg appointed President November 2025
Awards & Recognition
Nobel Prize in Chemistry 2024 awarded to founder Sir Demis Hassabis for AlphaFold work
Key Partnerships
Company Details
- Headquarters
- Lausanne, Switzerland
Work here?
Claim this listing to update company information and connect with our audience.
Claim This ListingOfficial Sources
Similar Companies in this Market
View all 64 →
A2A Pharmaceuticals
AI-driven pharmaceutical company focused on discovering and developing novel drug candidates using computational biology and machine learning.
AbCellera
AbCellera uses AI and machine learning to discover and develop antibody-based therapeutics and vaccines.
Absci
Absci uses AI-powered computational biology and machine learning to accelerate drug discovery and optimize therapeutic proteins and antibodies.
Adaptyv Bio
11-50 employees
Adaptyv Bio operates the world's fastest protein validation lab, providing automated experimental testing services for AI-designed proteins. The company enables protein engineers to validate binding, expression, and thermostability of novel protein designs through a fully automated platform with 3-week turnaround times.
Aitia
Aitia is a drug discovery and development company leveraging AI and computational biology to identify novel therapeutic targets and accelerate drug development.
Anagenex
Anagenex is a biotechnology company focused on drug discovery and development. The company appears to operate in the pharmaceutical research space, though specific details about their technology platform, therapeutic areas, and target markets are not available from the provided content.
Aqemia
Aqemia is a drug discovery company advancing next-generation medicines using generative AI and deep physics. The company combines AI-augmented discovery with computational chemistry to develop novel therapeutics at scale.
Arctoris
51-200 employees
Arctoris is a Partnership Research Organisation (PRO) providing automated wet lab biology R&D and data generation services for biotech, techbio, and pharma companies through its Ulysses® robotic platform.
Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as funding figures, employee counts, and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.